Mode
Text Size
Log in / Sign up

High Lp-PLA2 levels triple recurrent stroke risk in ischemic stroke patientsHigh Lp-PLA2 levels linked to higher risk of stroke recurrence

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Lp-PLA2 as a prognostic marker for recurrent stroke risk, but interpret cautiously due to observational data.

This meta-analysis pooled data from 2527 patients with ischemic stroke to evaluate the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and the risk of recurrent cerebrovascular events. The analysis included studies comparing high versus low Lp-PLA2 levels, as well as continuous-variable analyses.

The primary finding was a significantly increased risk of recurrent events in patients with high Lp-PLA2 levels, with a pooled relative effect estimate of 2.99 (95% CI 2.24-3.99; P < 0.001). A sensitivity analysis excluding a study without a cutoff value yielded a similar estimate of 2.76 (95% CI 2.20-3.47; P < 0.001). In continuous-variable analysis, each 1-standard deviation increase in Lp-PLA2 was associated with a pooled odds ratio of 2.62 (95% CI 1.08-6.33; P = 0.033).

The authors suggest that Lp-PLA2 may be a promising prognostic marker for secondary prevention after ischemic stroke. However, the analysis is based on observational studies, so the association does not prove causation. Limitations were not reported, and details on follow-up duration and study settings were not available.

Clinically, these findings support considering Lp-PLA2 as a potential risk stratification tool, but further prospective studies are needed to confirm its utility and to determine whether targeting Lp-PLA2 improves outcomes.

When someone survives a stroke, the biggest fear is often the next one. Doctors are looking for reliable ways to predict who might face another medical emergency. A large review of data from over 2,500 patients suggests that a specific protein in the blood, called Lp-PLA2, could be a helpful tool for this prediction.

The analysis found that patients with high levels of this protein faced a significantly higher risk of having another cerebrovascular event. Even when looking at the data in different ways, the link remained consistent. This suggests that measuring Lp-PLA2 could help doctors better understand a patient's risk profile after their initial stroke.

While these results are promising for identifying high-risk patients, it is important to remember that this is an association found in observational data. This means the protein is a marker that helps predict risk, but it does not cause the stroke itself. Talk to your doctor about how these markers might apply to your specific health plan.

What this means for you:
Higher levels of the Lp-PLA2 protein are linked to a higher risk of repeat strokes in patients.

Common questions

What is Lp-PLA2 and why does it matter?

Lp-PLA2 is a protein found in the blood. This study looked at how its levels relate to the risk of having another stroke. The results showed that patients with high levels of this protein had a significantly higher risk of experiencing another cerebrovascular event compared to those with lower levels.

Can this test help predict a second stroke?

The data suggests that Lp-PLA2 may be a promising marker for secondary prevention. Because high levels were linked to a higher risk of repeat events, it could help doctors identify which patients need closer monitoring or more intensive care after their first stroke.

Study Details

Study typeMeta analysis
Sample sizen = 2,527
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVE: To systematically evaluate the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and the risk of recurrent cerebrovascular events in patients with ischemic stroke. METHODS: PubMed, Web of Science, Embase, the Cochrane Library, and China National Knowledge Infrastructure were systematically searched from inception to May 20, 2026. Observational studies reporting the association between Lp-PLA2 levels and the risk of recurrent cerebrovascular events in patients with ischemic stroke were included. The primary outcome was recurrent cerebrovascular events, mainly including ischemic stroke, acute cerebral infarction, or cerebral infarction recurrence. Because studies comparing high versus low Lp-PLA2 levels reported both hazard ratios (HR) and odds ratios (OR), the pooled results were expressed as pooled relative effect estimates with 95% confidence intervals (CI). For the continuous-variable analysis, effect estimates were rescaled and expressed as ORs per 1 standard deviation (SD) increase in Lp-PLA2. All meta-analyses were performed using random-effects models. RESULTS: Ten studies involving 2,527 patients with ischemic stroke were included in the meta-analysis. Higher Lp-PLA2 levels were associated with an increased risk of recurrent cerebrovascular events (pooled relative effect estimate = 2.99, 95% CI 2.24-3.99; P < 0.001). After excluding the study that did not report the cutoff value for the high and low Lp-PLA2 groups, the association remained stable (pooled relative effect estimate = 2.76, 95% CI 2.20-3.47; P < 0.001). In the continuous-variable analysis, each 1-SD increase in Lp-PLA2 was associated with an increased risk of recurrent cerebrovascular events (pooled OR = 2.62, 95% CI 1.08-6.33; P = 0.033). CONCLUSION: Higher Lp-PLA2 levels are associated with an increased risk of recurrent cerebrovascular events in patients with ischemic stroke. Lp-PLA2 may be a promising prognostic marker for secondary prevention after ischemic stroke.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.